Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

NeurAxis to Host Third Quarter 2026 Results and Business Update Call on Monday, November 9, 2026

globenewswire.com
NRXS The article announces NeurAxis will host its third quarter 2026 results and business update call. It provides details for the call and a brief overview of the company's medical technology and FDA-cleared IB-Stim product. No specific financial results or forward-looking statements are made in this announcement.

NeurAxis to Host Third Quarter 2026 Results and Business Update Call on Monday, November 9, 2026 CARMEL, Ind., Oct. 27, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report summarized financial results for its third quarter period ended September 30, 2026, on Monday, November 9, 2026, before market open. The Company has scheduled a conference call for the same day, Monday, November 9, 2026, at 9:00 am ET to review the results.

Conference Call Details

Date and Time: Monday, November 9, 2026, at 9:00am ET

Toll Free: 1-833-862-0272 (U.S. and Canada toll-free) International: 1-412-634-5915

Webcast: https://app.webinar.net/B2bPr8Dro8e

Replay: Toll Free: 1-855-669-9658 (U.S. and Canada toll-free) International: 1-412-317-0088

Replay access code: 9067695

Webcast: https://app.webinar.net/B2bPr8Dro8e

About NeurAxis, Inc.

NeurAxis, Inc., is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. NeurAxis is dedicated to advancing science and leveraging evidence-based medicine to drive adoption of IB-Stim® , which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim is FDA cleared for functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD), and FD-related nausea symptoms in patients 8 years and older. Additional clinical trials of PENFS in multiple pediatric and adult conditions with large unmet healthcare needs are underway.

For more information, please visit http://neuraxis.com.

Investor Relations

Lytham Partners

Ben Shamsian

646-829-9701

shamsian@lythampartners.com